One group that is looking much better today is biotechnology.
This action may actually help to create some entry points.
The stock faces a lot of headwinds on a day when markets are trying to surmount trade-war woes.
After Friday's surge another look at BIIB is warranted.
Real Money reveals the crucial component Biogen got right in this trial and what it plans for the drug next.
Investors might be finally recognizing the hidden value of the firms' drug research and development.
Let's go to the charts.
There are issues in the study that are keeping some buyers cautious and causing selling into the early strength.
With biotech names getting some attention this morning a quick review looks like a good idea.
This biotech's weekly chart is very encouraging.

Columnist Conversations

Texas Instruments (TXN) announced after the close that CEO Brian Crutcher resigned due to violations of the c...
The initial upside target off the recent low comes in around the 333.51-337.71 area. Here is the updated ch...
A cup/handle is one of the strongest and most precise chart patterns out there, proven more often than not.&nb...
Today is 12 days up from the 6/28 low which is very similar to prior rallies of 11-13 days up.  This is r...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.